HHLA2 and colorectal carcinoma: Critically, a significant inhibition of tumor proliferation, migration, and invasion observed upon silencing HHLA2 in CRC cells pointed the HERV-H as a promising target for drug development in CRC treatment (Wang H. et al., 2024).